Does neoadjuvant chemoradiation improve resection rates for esophageal adenocarcinoma patients?
Neoadjuvant chemoradiation (nCRT) is a standard treatment before surgery for esophageal cancer. For esophageal adenocarcinoma specifically, research shows that adding radiation to chemotherapy does not increase the number of patients who undergo surgery (resection rate). However, it does improve the likelihood of a complete (R0) resection, where no cancer cells are left at the edges of the removed tissue. This distinction matters because R0 resection is linked to better outcomes.
What the research says
A 2024 meta-analysis of nine randomized trials including over 1,100 adenocarcinoma patients found that nCRT did not significantly improve overall resection rates compared to neoadjuvant chemotherapy alone (odds ratio 0.90, not statistically significant) 2. However, nCRT did lead to significantly more R0 resections (odds ratio 2.94, p=0.002) 2. This means that while the same proportion of patients undergo surgery, those receiving nCRT are more likely to have a complete removal of the tumor.
Another analysis from a large registry (AGAMENON-SEOM) compared perioperative FLOT chemotherapy to CROSS-based nCRT and found that while nCRT yielded higher R0 and pathological complete response rates, the estimated cure rate was similar between the two approaches 5. This suggests that the benefit of nCRT on resection quality may not always translate into higher cure rates.
Additionally, a systematic review on pathologic complete response (pCR) as a surrogate for overall survival found that for esophageal adenocarcinoma, pCR is a strong surrogate (R²=0.886, p<0.001) 3. Since nCRT increases pCR rates in squamous cell carcinoma but not significantly in adenocarcinoma 2, this may explain why the survival benefit of nCRT is less clear for adenocarcinoma.
A community-based study noted significant variability in neoadjuvant regimens used for esophageal adenocarcinoma, with no single regimen showing a survival advantage 4. This highlights that while nCRT can improve R0 rates, the optimal regimen remains uncertain.
What to ask your doctor
- Based on my specific tumor stage and location, what is the expected benefit of adding radiation to chemotherapy before surgery?
- How does the R0 resection rate with neoadjuvant chemoradiation compare to other options like perioperative FLOT chemotherapy?
- What are the risks of additional side effects from chemoradiation versus chemotherapy alone?
- Are there any ongoing trials comparing newer neoadjuvant regimens for esophageal adenocarcinoma?
- How does my overall health and tumor biology influence the choice between neoadjuvant chemoradiation and chemotherapy?
This question is drawn from common patient questions about Gastroenterology and answered using cited medical research. We do not provide individualized advice.